The Johns Hopkins paper in Nature Medicine, published March 19, followed 174,678 adults with type 1 diabetes on GLP-1 receptor agonists against matched controls and found a 15% reduction in major adverse cardiovascular events, a 19% reduction in end-stage renal disease, an 18% reduction in hypoglycemia hospitalization, and a 17% reduction in diabetic ketoacidosis hospitalization. [1] The paper's Saturday read named the document an actuarial cover for off-label prescribing in T1D.

The cover is now in use. The American Diabetes Association said Saturday it is reviewing the findings; JDRF has not yet stated a position. [2] The Centers for Medicare and Medicaid Services has issued no coverage guidance. The 174,678-patient cohort makes the prescribing question quantitative — the malpractice argument against off-label use loses its edge when the evidence base is twice the size of most pivotal trials.

What the week opens with the paper installed is the GLP-1 generation eating Cinco de Mayo. The week's home-cooking calendar — birria, mole, elote, sopapillas — runs into a population that is shrinking portions, leading with protein, and treating salsa as a vegetable. The demographic-winter thread acquires another data point: T1D outcomes get better while CMS coverage stays narrow, and the off-label market grows under that cap.

The June ADA conference will produce the first organizational position. CMS will follow, or not.

-- KENJI NAKAMURA, Baltimore